ePharma Physician® Research Study and Advisory Service Focused on Physician IT Adoption

Manhattan ResearchePharma Physician® is a syndicated multi-client research study and advisory service focused on physician information technology adoption. Specifically, the study examines how technology is levered by pharmaceutical, biotech, and device companies to improve relationships with physicians. Fielded annually, ePharma Physician® builds upon Manhattan Research's population-level physician research Taking the Pulse® and probes deeper into the audience of physicians interacting with pharmaceutical, device, and biotech companies online, currently about 80% of the physician population.

The study identifies and analyzes key attitudes, behaviors and psychographics of physicians who actively use online pharmaceutical services in order to help our clients better understand this key audience and meet its market demands.

Manhattan Research approach to ePharma Physician® is based on the belief that web log data alone cannot provide a full and representative picture of who visits web properties, why they go, or their subsequent actions taken. ePharma Physician® uses an online survey and recall methodology to offer the best means for understanding, benchmarking and measuring website effectiveness.

The ePharma Physician® strategic advisory service includes:

  • A comprehensive breakdown of physician satisfaction with top branded Rx product websites and top pharmaceutical and biotech corporate websites.
  • An analysis of growing physician demand for services such as customer service portals, live remote rep interactions, and closed-loop promotional integration.
  • Additional topics such as electronic detailing use and satisfaction; top blogs, podcasts, and specialty websites visited; and opinions regarding technology enabled sales reps (i.e., tablet PC use).

Better understand the audience of online physicians through ePharma Physician® and Manhattan Research.

For further information, please visit: http://www.manhattanresearch.com/products/Strategic_Advisory/ePP/default.aspx

About Manhattan Research
In addition to ePharma Physician®, Manhattan Research conducts numerous research studies among physicians and consumers in the United States and in Europe. Each study serves a unique purpose and focuses on different aspects of information technology adoption. Broad research is complemented by targeted analysis among more than 50 consumer therapeutic segments and 25 physician specialist segments. For further information, please visit www.manhattanresearch.com

Most Popular Now

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

Pfizer and BioNTech advance COVID-19 vaccine strat…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the companies have initiated a randomized, active-controlled, observer-blind, Phase 2 study to...

New needle-free nasal vaccine shows promise for CO…

New research shows that a needle-free mucosal bacteriophage (phage) T4-based COVID-19 vaccine is effective against SARS-CoV-2 infection. The findings were published in mB...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

Disparities in United States COVID-19 vaccine dist…

When reports showed COVID-19 vaccination rates were lower among racial/ethnic minority groups, most discussions focused on mistrust and misinformation among these populat...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

GSK signs agreement to support pandemic preparedne…

GSK plc (LSE/NYSE: GSK) announced it had signed a framework contract with the European Commission's (EC) Health Emergency Preparedness and Response Authority (HERA) for t...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

Scientists develop new biomimetic formulation for …

Glioblastoma multiforme (GBM) is an aggressive brain cancer with a poor prognosis and few treatment options. New and effective approaches for GBM treatment are therefore ...